EUVIMEDEUVIMED entdecken
Crossref

MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors

J Qu, T Zhang, X Zhang, W Zhang, Y Li, Q Gong, L Yao, S Lui

Clinical Radiology · 2024-04 · 79 (4) · e582-e591

DOI: 10.1016/j.crad.2024.01.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Radiology, 2024-04. Verfasst von J Qu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, and Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital of Sichuan University, Chengdu,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Sichuan Province Science and Technology Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: To identify clinical and magnetic resonance imaging (MRI) radiomics predictors specialised for intracranial progression (IP) after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in non-small-cell lung cancer (NSCLC) patients with brain metastases (BMs). MATERIALS AND METHODS: Seventy EGFR-mutated NSCLC patients with a total of 212 BMs who received first-line EGFR-TKI therapy were enrolled. Radiomics features were extracted from the BM regions on the pretreatment contrast-enhanced T1-weighted images, and the radiomics score (rad-score) of each BM was established based on the selected features. Furthermore, the mean rad-score derived from the average rad-score of all included BMs in each patient was calculated. Univariate and multivariate logistic regression analyses were performed to identify potential predictors of IP. Prediction models based on different predictors and their combinations were constructed, and nomogram based on the optimal prediction model was evaluated. RESULTS: Thirty-three (47.1 %) patients developed IP, and the remaining 37 (52.9 %) patients were IP-free. EGFR-19del mutation (OR 0.19, 95 % CI 0.05-0.69), third-generation TKI treatment (OR 0.33, 95 % CI 0.16-0.67) and mean rad-score (OR 5.71, 95 % CI 1.65-19.68) were found to be independent predictive factors. Models based on these three predictors alone and in combination (combined model) achieved AUCs of 0.64, 0.64, 0.74, and 0.86 and 0.64, 0.64, 0.75, and 0.84 in the training and validation sets, respectively, and the combined model demonstrated optimal performance for predicting IP. CONCLUSIONS: The model integrating EGFR-19del mutation, third-generation TKI treatment and mean rad-score had good predictive value for IP after EGFR-TKI treatment in NSCLC patients with BM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBrain NeoplasmsHumansTyrosine Kinase InhibitorsRadiomicsTreatment OutcomeProtein Kinase InhibitorsErbB ReceptorsMagnetic Resonance ImagingMutationRetrospective Studies

Substanzen

Tyrosine Kinase InhibitorsProtein Kinase InhibitorsErbB Receptors

Autor:innen und Institutionen

  • Department of Radiology, and Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital of Sichuan University, Chengdu, China; Huaxi MR Research Center (HMRRC), West China Hospital of Sichu…
  • Department of Computer Science and Engineering, University of Electronic Science and Technology of China, Chengdu, China.
  • Pharmaceutical Diagnostic Team, GE Healthcare, Life Sciences, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Sichuan Province Science and Technology Support Program
  • Sichuan University
  • Chinese Academy of Meteorological Sciences

Zitieren

APA

Qu, J., Zhang, T., Zhang, X., Zhang, W., Li, Y., Gong, Q., Yao, L., & Lui, S. (2024). MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clinical Radiology, 79(4), e582-e591. https://doi.org/10.1016/j.crad.2024.01.005

Vancouver

Qu J, Zhang T, Zhang X, Zhang W, Li Y, Gong Q, et al. MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clinical Radiology. 2024;79(4):e582-e591. doi:10.1016/j.crad.2024.01.005

BibTeX
@article{Qu2024,
  author = {Qu, J and Zhang, T and Zhang, X and Zhang, W and Li, Y and Gong, Q and Yao, L and Lui, S},
  title = {MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors},
  journal = {Clinical Radiology},
  year = {2024},
  volume = {79},
  number = {4},
  pages = {e582--e591},
  doi = {10.1016/j.crad.2024.01.005}
}
Kostenlos starten →